Dendritic cell (DC)-tumor fusion hybrid vaccinees that facilitate antigen presentation represent a novel powerful strategy in cancer immunotherapy. Preclinical studies have demonstrated that IL-12 promotes specific antitumor immunity mediated by T cells in several types of tumors. In the present study, we investigated the antitumor immunity derived from vaccination of fusion hybrids between DCs and engineered J558/IL-12 myeloma cells secreting Th1 cytokine IL-12.
Methods
The expression vector pcDNA-IL-12 was generated and transfected into J558 myeloma cells and then bone marrow-derived DCs were fused with engineered J558/IL-12 cells. The antitumor immunity derived from vaccination of the fusion hybrid DC/J558/IL-12 was evaluated in vitro and in vivo.
Results
DC/J558/IL-12 cells secreted recombinant IL-12 (1.6 ng/mL), and inoculation of BALB/c mice with DC/J558/IL-12 hybrid induced a Th1 dominant immune response and resulted in tumor regression. Immunization of mice with engineered DC/J558/IL-12 hybrid elicited stronger J558 tumor-specific cytotoxic T lymphocyte (CTL) responses in vitro as well as more potent protective immunity against J558 tumor challenge in vivo than immunization with the mixture of DCs and J558/IL-12, J558/IL-12 and J558, respectively. Furthermore, the antitumor immunity mediated by DC/J558/1L-12 tumor cell vaccination in vivo appeared to be dependent on CD8+ CTL.
Conclusions
These results demonstrate that the engineered fusion hybrid vaccines that combine Th1 cytokine gene-modified tumor cells with DCs may be an attractive strategy for cancer immunotherapy.
MeliefC.J., KastW.M.: Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.Adv Cancer Res, 58: 143–175, 1992.
2.
TownsendA., TrowsdaleJ.: The transporters associated with antigen presentation.Semin Cell Biol, 4: 53–61, 1993.
3.
YewdellJ.W., BenninkJ.R.: Cell biology of antigen processing and presentation to MHC class I molecule restricted T lymphocytes.Adv Immunol, 52: 1–123, 1992.
4.
ChenL., AsheS., BradyW.A., HellstromI., HellstromK.E., Led-betterJ.A., McGowanP., LinsleyP.S.: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecule CD28 and CTLA-4.Cell, 7: 1093–1102, 1992.
5.
ChenH.L., GabrilovichD., TampeR., GirgisK.R., NadafS., CarboneD.P.: A functional defective allele of TAPI results in loss of MHC class I antigen presentation in a human lung cancer.Nat Genet, 13: 210–213, 1996.
6.
ArmstrongT.D., ClementsV.K., MartinB.K., TingJ.P., Ostrand-RosenbergS.: Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.Proc Natl Acad Sci USA, 94: 6886–6891, 1997.
7.
HockH., DorschM., KunzendorfU., QinZ., DiamantsteinT., BlankensteinT.: Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor and interferon gamma.Proc Natl Acad Sci USA, 90: 2774–2778, 1993.
8.
MaricM., LiuY.: Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1 -expressing tumor: linkage between inflammation and specific immunity.Cancer Res, 59: 5549–5553, 1999.
9.
HuangA.Y., GolumbekP., AhmadzadehM., JaffeeE., PardollD., LevitskyH.: Role of bone marrow-derived cells in presenting MHC class I restricted tumor antigens.Science, 264; 961–965, 1994.
10.
MayordomoJ.I., ZorinaT., StorkusW.J., ZitvogelL., CelluzziC., FaloL.D., MeliefC.J., IldstadS.T., KastW.M., DeleoA.B.: Bone marrow-derived dendritic cells pulsed with synthetic tumor peptide elicit protective and therapeutic antitumor immunity.Nature Med, 1: 1297–1302, 1995.
11.
AshleyD.M., FaiolaB., NairS., HaleL.P., BignerD.D., GilboaE.: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors.J Exp Med, 186: 1177–1182, 1997.
12.
NestleF.O., AlijagicS., GillietM., SunY., GrabbeS., DummerR., BurgG., SchadendorfD.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.Nat Med, 4: 328–332, 1998.
13.
TimmermanJ.M., LevyR.: Dendritic cell vaccines for cancer immunotherapy.Annu Rev Med, 50: 507–529, 1999.
14.
GuoY., WuM., ChenH., WangX., LiuG., LiG., MaJ., SyM.S.: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells.Science, 263: 518–520, 1994.
15.
GongJ., ChenD., KashiwabaM., KufeD.: Induction of antitumor activity by immunization with fusion of dendritic and carcinoma cells.Nature Med, 3: 558–560, 1997.
16.
GongJ., ChenD., KashiwabaM., LiY., ChenL., TakeuchiH., QuH., RowseG.J., GendlerS.J., KufeD.: Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells.Proc Natl Acad Sci USA, 95: 6279–6283, 1998.
17.
MosmannT.R., SadS.: The expanding universe of T-cell subsets: Thl, Th2 and more.Immunol Today, 17: 138–146, 1996.
18.
NishimuraT., IwakabeK., SekimotoM., OhmiY., YahataT., NakuiM., SatoT., HabuS., TashiroH., SatoM., OhtaA.: Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo.J Exp Med, 190: 617–627, 1999.
19.
ItoN., NakamuraH., TanakaY., OhgiS.: Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry.Cancer, 85: 2359–2367, 1999.
20.
RissoanM.C., SoumelisV., KadowakiN., GrouardG., BriereF., de-Waal-MalefytR., LiuY.J.: Reciprocal control of T helper cell and dendritic cell differentiation.Science, 83: 1183–1186, 1999.
21.
MaldonadoL.R., De-SmedtT., MichelP., GodfroidJ., PajakB., HeirmanC., ThielemansK., LeoO., UrbainJ., MoserM.: CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo.J Exp Med, 189: 587–592, 1999.
22.
PulendranB, SmithJ.L., CasparyG., BraselK., PettitD., MaraskovskyE., MaliszewskiC.R.: Distinct dendritic cell subsets differentially regulate the class of immune response in vivo.Proc Natl Acad Sci USA, 96: 1036–1041, 1999.
23.
SatoM., IwakabeK., OhtaA., SekimotoM., NakuiM., KodaT., KimuraS., NishimuraT.: Functional heterogeneity among bone marrow-derived dendritic cells conditioned by T(h)1-and T(h)2-biasing cytokines for the generation of allogeneic cytotoxic T lymphocytes.Int Immunol, 12: 335–342, 2000.
24.
KobayashiM., FitzL., RyanM., HewickR.M., ClarkS.C., ChanS., LoudonR., ShermanF., PerussiaB., TrinchieriG.: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.J Exp Med, 170: 827–845, 1989.
TrinchieriG.: Interleukin-12: A cytokine at the interface of inflammation and immunity.Adv Immunol, 70: 83–243, 1998.
27.
SongW., KongH.L., CarpenterH., ToriiH., GransteinR., RafiiS., MooreM.A., CrystalR.G.: Dendritic cells genetically modified with adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity.J Exp Med, 186: 1247–1256, 1997.
28.
LutzM.B., SuriR.M., NiimiM., OgilvieA.L., KukutschN.A., RossnerS., SchulerG., AustynJ.M.: Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo.Eur J Immunol, 30: 1813–1822, 2000.
29.
WangJ., SaffoldS., CaoX., KraussJ., ChenW.: Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.J Immunol, 161: 5516–5524, 1998.
30.
XiangJ., MoyanaT.: Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1.J Interferon Cytokine Res, 20: 349–354, 2000.
31.
AdrisS., ChuluyanE., BravoA., BerensteinM., KleinS., JasnisM., CarboneC., ChernajovskyY., PodhajcerO.L.: Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells.Cancer Res, 60: 6696–6703, 2000.
32.
ColomboM.P., TrinchieriG.: Interleukin-12 in antitumor immunity and immunotherapy.Cytokine Growth Factor Rev, 13: 155–168, 2002.
33.
CohenJ.: IL-12 deaths: explanation and a puzzle.Science (Washington DC), 270: 908, 1995.
WangJ., SaffoldS., CaoX., KraussJ., ChenW.: Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.J Immunol, 161: 5516–5524, 1998.
36.
MartenA., RenothS., HeinickeT., AlbersP., PauliA., MeyU., CaspariR., FliegerD., HanflandP., Von RueckerA., Eis-HubingerA.M., MullerS., SchwanerI., LohmannU., HeylmannG., SauerbruchT., Schmidt-WolfI.G.: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.Hum Gene Ther, 14: 483–494, 2003.
37.
KikuchiT., AkasakiY., IrieM., HommaS., AbeT., OhnoT.: Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.Cancer Immunol Immunother, 50: 337–344, 2001.
38.
CaoX., ZhangW., WangJ., ZhangM., HuangX., HamadaH., ChenW.: Therapy of established tumor with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.Immunology, 97: 616–625, 1999.
CroftM., CarterI., SwainS., DuttonR.: Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles.J Exp Med, 180: 1715–1728, 1994.
41.
McKnightA.J., ZimmerG.J., FogelmanI., WolfS.F., AbbasA.K.: Effects of IL-12 on helper T cell-dependent immune responses in vivo.J Immunol, 152: 2172–2179, 1994.
42.
RempelJ.D., WangM.D., Hay GlassK.T.: In vivo IL-12 administration induces profound but transient commitment to T helper cell type 1-associated patterns of cytokine and antibody production.J Immunol, 159: 1490–1496, 1997.
43.
RodolfoM., MelaniC., ZilocchiC., CappettiB., LuisonE., ArioliI., ParenzaM., CanevariS., ColomboM.P.: IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgGl induced by IL-4 vaccine is associated with the eradication of experimental metastases.Cancer Res, 58: 5812–5817, 1998.
